无症状肠系膜动脉闭塞性疾病的自然史及症状进展预测因素
单中心回顾性分析79例影像学诊断的腹腔或肠系膜上动脉>70%狭窄患者,分为无症状MAOD组43例与症状性CMI组36例。无症状组平均随访32.7±30.2个月,无1例出现症状。症状组更常有吸烟史(P=.02)且较少抗凝(P<.01),影像上更常见SMA重度狭窄(P<.001)、多血管病变(P=.001)、钙化主动脉斑块(P=.01)及髂内动脉重度狭窄(P<.001)。多因素分析示未抗凝(P<.01)和SMA重度狭窄(P<.001)与症状性表现独立相关。
要点
- 无症状MAOD在诊断后2~3年内进展为CMI的比例似乎极低。
- 症状性CMI患者更常有吸烟史且较少使用抗凝治疗。
- SMA狭窄严重程度、抗凝使用及可能吸烟史和主动脉斑块钙化或可分层缺血进展风险。
核心结论
- 无症状MAOD进展为CMI的比率在诊断后2~3年内似乎极低,提示预防性血运重建大多不必要。
- 无症状MAOD的监测可基于疾病的临床和影像学特征进行个体化。
- SMA狭窄严重程度、抗凝使用以及可能的吸烟史和主动脉斑块钙化可能是分层缺血进展风险的有前景标志物。
研究设计与样本
- 单中心回顾性分析,纳入机构放射学数据库中轴位影像或双功能超声诊断的腹腔或肠系膜上动脉>70%狭窄患者。
- 共79例符合标准,分为无症状MAOD组43例和症状性CMI组36例,分组依据为初诊时临床表现。
- 主要终点为从无症状狭窄进展为CMI。
主要发现
- 无症状组平均随访32.7±30.2个月,60.5%(n=26)转诊至血管外科医师随访21.5±27.8个月,随访期间无患者出现症状。
- 症状组所有患者均由血管外科医师评估并在诊断后6个月内接受CMI手术干预。
- 症状组较无症状组更常有吸烟史(P=.02)且较少抗凝(P<.01);症状组冠状动脉疾病患病率有更高趋势(P=.06),心律失常患病率有更低趋势(P=.08)。
- 影像上症状组更常见SMA重度狭窄(P<.001)、多血管肠系膜病变(P=.001)、钙化主动脉斑块(P=.01)及一侧或双侧髂内动脉重度狭窄(P<.001)。
- 多因素分析示未抗凝(P<.01)和SMA重度狭窄(P<.001)与症状性肠系膜狭窄更高比值比独立相关;钙化主动脉斑块(P=.08)和吸烟史(P=.06)虽有更高比值比趋势但未达统计学显著。
关键数值与推荐
- 无症状MAOD组43例,症状性CMI组36例,共79例。
- 无症状组平均随访32.7±30.2个月,60.5%(n=26)转诊血管外科随访21.5±27.8个月。
- 症状组吸烟史P=.02,抗凝P<.01,冠状动脉疾病P=.06,心律失常P=.08。
- 症状组SMA重度狭窄P<.001,多血管肠系膜病变P=.001,钙化主动脉斑块P=.01,髂内动脉重度狭窄P<.001。
- 多因素分析:未抗凝P<.01,SMA重度狭窄P<.001,钙化主动脉斑块P=.08,吸烟史P=.06。
临床怎么用
- 原文结论认为无症状MAOD进展为CMI的比率似乎极低,提示预防性血运重建大多不必要。
- 原文结论认为无症状MAOD的监测可基于疾病的临床和影像学特征进行个体化。
- 原文结论认为SMA狭窄严重程度、抗凝使用以及可能的吸烟史和主动脉斑块钙化可能是分层缺血进展风险的有前景标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to characterize the natural history of incidentally identified asymptomatic mesenteric artery stenosis and to identify clinical and radiographic predictors that differentiate patients with asymptomatic mesenteric artery occlusive disease (MAOD) and patients with symptomatic chronic mesenteric ischemia (CMI) diagnosed at the index study. METHODS: This single-institution retrospective analysis included patients diagnosed with >70% stenosis of the celiac or superior mesenteric artery (SMA) on axial imaging or duplex ultrasound examination in an institutional radiology database. Patients were grouped into asymptomatic MAOD and symptomatic CMI cohorts according to their clinical presentation at index study. The primary end point was progression of disease from asymptomatic stenosis to CMI. Demographic, clinical, and imaging features at index study were also compared between asymptomatic and symptomatic cohorts. RESULTS: Seventy-nine patients met the inclusion criteria, with 43 in the asymptomatic group and 36 in the symptomatic group. Patients in the asymptomatic group were followed for mean 32.7 ± 30.2 months; 60.5% (n = 26) were referred to and followed by a vascular surgeon for 21.5 ± 27.8 months. No asymptomatic patients developed symptoms during the follow-up period. All patients in the symptomatic group were evaluated by a vascular surgeon and underwent procedural intervention for CMI within 6 months of diagnosis. Patients with CMI were more likely to have a history of smoking (P = .02) and less likely to be anticoagulated (P < .01) than patients with asymptomatic MAOD. Symptomatic patients trended toward a greater prevalence of coronary artery disease (P = .06) and a lower prevalence of arrhythmia (P = .08). On imaging, the symptomatic cohort was more likely to have severe SMA stenosis (P < .001), multivessel mesenteric disease (P = .001), calcified aortic plaque (P = .01), and severe stenosis in one or both internal iliac arteries (P < .001). On multivariable analysis, a lack of anticoagulation use (P < .01) and severe SMA stenosis (P < .001) were associated independently with higher odds of symptomatic mesenteric stenosis. Although statistically insignificant, calcified aortic plaque (P = .08) and smoking history (P = .06) trended toward higher odds of symptomatic index presentation. CONCLUSIONS: The rate of progression from asymptomatic MAOD to CMI seems to be exceedingly low in the first 2 to 3 years after diagnosis, suggesting that prophylactic revascularization is mostly unnecessary. Surveillance of asymptomatic MAOD may be personalized based on clinical and radiographic features of disease. SMA stenosis severity, anticoagulation use, and possibly smoking history and the presence of aortic plaque calcification may be promising markers to stratify the risk of ischemic progression.
引用
- Harish KB, Chervonski E, Rokosh RS, et al. Natural history of asymptomatic mesenteric artery occlusive disease and predictors of symptomatic progression. J Vasc Surg. 2025. PMID: 40254189. doi:10.1016/j.jvs.2025.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。